The accolade recognizes the product's unique dual-action composition, which bridges the gap between traditional skin boosters and dermal fillers. By combining cross-linked hyaluronic acid with a protective buffer of 15 amino acids, the treatment targets both structural dermal support and aesthetic refinement. This formulation is designed to improve hydration, firmness, and texture while providing a subtle lifting effect for fine lines and wrinkles.

Dr. Javed Hussain, a key opinion leader for the manufacturer, noted that the product delivers reproducible, reliable outcomes. He emphasized that the integration of an amino acid buffer supports the restoration of natural dermal functions that typically decline with age, offering a level of durability currently unmatched by standard booster treatments. Patients generally report immediate visual improvements followed by progressive gains in skin quality in the weeks following the procedure.

Skin Tech Pharma Group, based in Costa Brava, Spain, marks this milestone as part of its 30th anniversary. Founded in 1994 by Dr. Philippe Deprez, the company continues to focus on evidence-based medical devices that combine pharmaceutical rigor with aesthetic performance. CEO Márcio Rodrigues stated that the award serves as a validation of the firm's long-term strategy, which prioritizes scientific innovation and the evolving needs of healthcare professionals in the regenerative medicine sector.